Documents
Application Sponsors
NDA 213593 | AZURITY PAHRMACEUTICALS, INC | |
Marketing Status
Application Products
001 | SUSPENSION;ORAL | 2MG; 84MG / ML | 0 | KONVOMEP | OMEPRAZOLE AND SODIUM BICARBONATE |
FDA Submissions
TYPE 5; Type 5 - New Formulation or New Manufacturer | ORIG | 1 | AP | 2022-08-30 | STANDARD |
Submissions Property Types
CDER Filings
AZURITY PAHRMACEUTICALS, INC
cder:Array
(
[0] => Array
(
[ApplNo] => 213593
[companyName] => AZURITY PAHRMACEUTICALS, INC
[docInserts] => ["Medication Guide","https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/213593s000lbl.pdf#page=28"]
[products] => [{"drugName":"KONVOMEP","activeIngredients":"OMEPRAZOLE AND SODIUM BICARBONATE","strength":"2MG; 84MG \/ ML","dosageForm":"SUSPENSION;ORAL","marketingStatus":"Prescription","te":"None","rld":"No","rs":"No"}]
[labels] => [{"actionDate":"08\/30\/2022","submission":"ORIG-1","supplementCategories":"Approval","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2022\\\/213593s000lbl.pdf\"}]","notes":""}]
[originalApprovals] => [{"actionDate":"08\/30\/2022","submission":"ORIG-1","actionType":"Approval","submissionClassification":"Type 5 - New Formulation or New Manufacturer","reviewPriority":"STANDARD","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2022\\\/213593s000lbl.pdf\"},{\"name\":\"Letter (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/appletter\\\/2022\\\/213593Orig1s000ltr.pdf\"}]","notes":">"}]
[supplements] =>
[actionDate] => 2022-08-30
)
)